| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802282601016 | 228260101 | EPIVIR F.C.TAB 150MG/TAB FLX60 (HDPE) | 52.77 | 55.36 | 70.42 |
| 05/2018 | 2802282602013 | 228260201 | EPIVIR ORAL.SOL 10MG/ML FLX240ML | 16.21 | 17.01 | 23.44 |
| 05/2018 | 2802282603010 | 228260301 | EPIVIR F.C.TAB 300MG/TAB BTX30(HDPE) | 56.00 | 58.75 | 74.73 |
For the treatment of HIV infection and chronic hepatitis B (HBV).
Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.
Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in adults is 86% ± 16% for the tablet and 87% ± 13% for the oral solution.
5 to 7 hours
The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase to form the 5′-carboxylic acid and glucuronyl transferase to form the 5′-glucuronide. Lamivudine is excreted in human breast milk and into the milk of lactating rats.
* Renal cl=280.4 +/- 75.2 mL/min [HIV-infected patients given a single IV doses ranging from 0.25 to 8 mg/kg]